Search | Clinical Trials Finder

Conditions: Healthy Volunteers
Interventions: BMS-986278, Placebo, Moxifloxacin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 2
States / cities: San Antonio, Texas • Salt Lake City, Utah

Conditions: Amyotrophic Lateral Sclerosis, Healthy Volunteer
Interventions: SAR443820, Erythromycin ethyl succinate, Itraconazole; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Healthy Volunteers
Interventions: GSBR-1290 (Capsule/Tablet), GSBR-1290, Placebo, Placebo (Capsule/Tablet); Drug
Lead sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Miami, Florida • Baltimore, Maryland

Conditions: Healthy Volunteers
Interventions: Xanomeline/ Trospium Chloride; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Anaheim, California • Lenexa, Kansas • San Antonio, Texas

Conditions: Healthy Volunteers
Interventions: KarXT, KarX-EC, Placebo, Omeprazole; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 19 Years to 90 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Healthy Participants
Interventions: BMS-986322, Rosuvastatin, Metformin, Glucose, Methotrexate, Leucovorin; Drug · Dietary Supplement
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy Volunteer
Interventions: Tavapadon; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
Interventions: ALN-4324, Placebo; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: Montclair, California • Washington D.C., District of Columbia • Miami, Florida + 3 more

Conditions: Achondroplasia
Interventions: BMN 111, Normal Saline; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 22 Years to 45 Years · Male only
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Healthy Volunteers
Interventions: Itraconazole, Rifampin, Golcadomide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 2
States / cities: Atlanta, Georgia • Lenexa, Kansas

Conditions: Healthy Volunteers
Interventions: Fedratinib, Rifampin, Efavirenz; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Chemotherapy-induced Nausea and Vomiting
Interventions: Rolapitant; Drug
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteers
Interventions: ACP-196, Omeprazole; Drug
Lead sponsor: Acerta Pharma BV; Industry
Eligibility: 19 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Volunteers
Interventions: S-337395, Placebo; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Healthy Volunteers
Interventions: Zasocitinib, COC, Metformin, Digoxin, Esomeprazole; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Phenylketonuria
Interventions: JNT-517 Suspension, Placebo Suspension, JNT-517 Tablet, Placebo Tablet; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 11
States / cities: Gainesville, Florida • Tampa, Florida • Atlanta, Georgia + 8 more

Conditions: Healthy, Rheumatoid Arthritis
Interventions: IA-14069, Placebo, Methotrexate; Drug
Lead sponsor: ILAb Co., Ltd.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Healthy Study Participants
Interventions: UCB0599, Esomeprazole, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Glendale, California

Conditions: Cardiovascular Disease
Interventions: AZD3366, Placebo, Ticagrelor, acetylsalicylic acid (ASA); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Participants
Interventions: BMS-986365, Rabeprazole; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Healthy Participants, Alzheimer's Disease Dementia
Interventions: Emraclidine, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 11
States / cities: Cypress, California • San Diego, California • Hialeah, Florida + 8 more

Conditions: Systemic Lupus Erythematosus
Interventions: GSK4527363, Placebo matching GSK4527363, Belimumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 142 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 6
States / cities: Scottsdale, Arizona • Aurora, Colorado • Las Vegas, Nevada + 3 more

Conditions: Diabetes Mellitus
Interventions: JTT-251 or Placebo; Drug
Lead sponsor: Akros Pharma Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Healthy Volunteers
Interventions: CC-90001, Placebo; Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Austin, Texas

Search by objective public record fields.

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants

A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)

A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants

A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants

A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult Participants

A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy Participants

A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participants

A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM

A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult Volunteers

A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants

Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects

A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers

A Study to Evaluate the Effect of an Acidic Formulation of Acalabrutinib (ACP-196), Acidic Beverage, or Grapefruit Juice on the Pharmacokinetics (PK) of ACP-196 Alone and Coadministered With Omeprazole

A Study to Investigate Different Formulations of S-337395 in Healthy Adult Participants

A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults

First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria

MAD Study of IA-14069

A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharmacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects

Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants

A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease

A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants

Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects

First-in-human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001